• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

EPIX Pharmaceuticals to Present at UBS Global Life Sciences Conference

Posted on: Tuesday, 27 September 2005, 15:00 CDT

EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX), a developer of innovative pharmaceuticals for magnetic resonance imaging (MRI), announced today that its presentation at the UBS Global Life Sciences Conference will be webcast live.

Michael J. Astrue, EPIX Interim Chief Executive Officer, is scheduled to deliver the presentation, which will include an update on the clinical, regulatory and financial status of the Company, on Thursday, September 29, 2005 at 12:30 pm at the Grand Hyatt Hotel in New York City. The webcast of the presentation can be accessed live through the Investor Relations page of the Company's website, www.epixpharma.com. An archived version of the webcast will be available beginning three hours after the live presentation through October 29, 2005.

About EPIX

EPIX Pharmaceuticals, Inc., based in Cambridge, MA, discovers and develops innovative pharmaceuticals for imaging that are designed to transform the diagnosis, treatment and monitoring of disease. The Company uses its proprietary Target Visualization Technology(TM) to create imaging agents targeted at the molecular level, designed to enable physicians to use Magnetic Resonance Imaging (MRI) to obtain detailed information about specific disease processes. To receive the latest EPIX news and other corporate developments, please visit the EPIX website at www.epixpharma.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on current expectations of the Company's management. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond EPIX Pharmaceuticals' control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things: the inability to establish and maintain strong business relationships with leading pharmaceutical companies and medical device manufacturers; the failure to comply with federal and state statutes and regulations relating to EPIX Pharmaceuticals' products, including FDA requirements; that the completion of clinical studies may not prove the superiority of EPIX Pharmaceuticals' products; the inability to recruit a sufficient number of patients for clinical studies; the inability to adequately address issues raised by FDA in its review of EPIX Pharmaceuticals' submissions; the inability of EPIX Pharmaceuticals' partner(s) to achieve regulatory approval in the countries in which they plan to sell EPIX Pharmaceuticals' products; the inability of EPIX Pharmaceuticals to identify and interest potential partners in its technologies and products; the inability to protect EPIX Pharmaceuticals' intellectual property and the cost of enforcing or defending EPIX Pharmaceuticals in litigation relating to intellectual property rights. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. EPIX Pharmaceuticals undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional information regarding these and other risks faced by EPIX Pharmaceuticals, see the disclosure contained in EPIX Pharmaceuticals' periodic reports filed with the Securities and Exchange Commission, including but not limited to EPIX Pharmaceuticals' Form 10-K for the year ended December 31, 2004 and subsequent Forms 10-Q.

Source: Business Wire

More News in this Category